Dogwood Therapeutics, Inc. (DWTX)
DWTXNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$1.23
+0.0360 (+3.02%) today
At the close, Nov 10, 4:00 PM ET. After hours $1.23 –
- Market cap
- $47.02m
- P/E
- –
- EPS, last 4 quarters
- $-0.8900
- Dividend yield
- –
- Day range
- $1.17 to $1.34
- 52-week range
- $0.9010 to $7.04
- Average volume
- 82.1k
- Previous close
- $1.19
Analysts
2 coveringStrong Buy2 buy, 0 hold, 0 sell
Targets a year out average $13.50, +997.6% from here
Earnings
next estimate $-0.1600Next report
Dec 2025
+78.7%
Mar 2026
+31.8%
Jun 2026
-161.5%
Sep 2026
+6.7%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$15.81m | -$3.81m | -$5.08m | -$14.06m |
| Net income | -$15.74m | -$3.78m | -$4.99m | -$11.53m |
News
8 latest- Dogwood Therapeutics, Inc. Reports Third Quarter 2026 Financial Results and Closes $5 million Private PlacementFintel · 5 days ago
- Dogwood Completes Enrollment In Halneuron Phase 2b CINP Trial; Topline Data Due November RTTNews · Sep 14, 2026
- Biotech Movers: Modular Medical Jumps, InnovAge Revenue Up 16%, Pyxis Data On Deck, Dogwood In Focus RTTNews · Sep 8, 2026
- Dogwood Therapeutics Nears Phase 2b Readout for Halneuron Neuropathic Pain TreatmentMarketBeat · Sep 1, 2026
- Halneuron Shows Pain Relief Separation In Interim Phase 2b Trial RTTNews · Dec 23, 2025
- HC Wainwright & Co. Maintains Dogwood Therapeutics (DWTX) Buy RecommendationFintel · Sep 30, 2025
- Dogwood Secures License To Develop Serpin Pharma's IV Formulation Of SP16 RTTNews · Sep 29, 2025
- HC Wainwright & Co. Upgrades Dogwood Therapeutics (DWTX)Fintel · Apr 23, 2025
The company
Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing first-in-class, non-opioid medicines to treat pain and neuropathic disorders. Dogwood's research pipeline includes two first-in-class development candidates, Halneuron and SP16 IV. Our lead product candidate, Halneuron, is in Phase 2b development to treat pain conditions including the neuropathic pain associated with chemotherapy treatment. Halneuron has been granted fast track designation from the FDA for the treatment of CINP. Halneuron is a non-opioid, NaV 1.7 analgesic which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- virios.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.